{"id":82950,"date":"2026-05-08T17:12:58","date_gmt":"2026-05-08T11:42:58","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=82950"},"modified":"2026-05-08T17:13:00","modified_gmt":"2026-05-08T11:43:00","slug":"hcg-oncology-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/","title":{"rendered":"HCG Oncology Share Price Target 2026: Expert Forecast, Growth Catalysts and Key Risks"},"content":{"rendered":"<div class=\"meta-block\">\u00a0<\/div>\n<p>The <strong><a href=\"https:\/\/univest.in\/user\/stocks\/hcg\/healthcare-global-enterprises-ltd-share-price-today\">HCG Oncology<\/a> share price target<\/strong> for 2026 stands at Rs 470 as per the latest analyst forecast, implying 29 percent upside from the current market price of Rs 365. Investors tracking the <strong>HCG Oncology share price target 2026<\/strong> need to understand the full picture including growth catalysts, FY27 earnings timeline, key risks, and the bull vs bear case scenarios. This article covers every dimension of the <strong>HCG Oncology share price target<\/strong> thesis updated April 2026.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here to Get Free Investment Predictions on Univest<\/strong><\/a><\/p>\n<p>Track live HCG Oncology price, FII or DII flows and analyst targets on the <strong>Univest Screener<\/strong>.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#HCG_Oncology_Company_Overview\" title=\"HCG Oncology Company Overview\">HCG Oncology Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Why_Analysts_Set_the_HCG_Oncology_Share_Price_Target_at_Rs_470_for_2026\" title=\"Why Analysts Set the HCG Oncology Share Price Target at Rs 470 for 2026\">Why Analysts Set the HCG Oncology Share Price Target at Rs 470 for 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#FY27_Earnings_Delivery_and_Revenue_Acceleration\" title=\"FY27 Earnings Delivery and Revenue Acceleration\">FY27 Earnings Delivery and Revenue Acceleration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Revenue_scale-up_from_new_product_launches\" title=\"Revenue scale-up from new product launches\">Revenue scale-up from new product launches<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Margin_expansion_through_operating_leverage\" title=\"Margin expansion through operating leverage\">Margin expansion through operating leverage<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\" title=\"RBI Rate Cut Cycle and Lower Cost of Capital\">RBI Rate Cut Cycle and Lower Cost of Capital<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Union_Budget_2026-27_Policy_Support\" title=\"Union Budget 2026-27 Policy Support\">Union Budget 2026-27 Policy Support<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Bull_Case_Base_Case_and_Bear_Case_for_HCG_Oncology_Share_Price_Target\" title=\"Bull Case, Base Case and Bear Case for HCG Oncology Share Price Target\">Bull Case, Base Case and Bear Case for HCG Oncology Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Key_Risks_to_the_HCG_Oncology_Share_Price_Target\" title=\"Key Risks to the HCG Oncology Share Price Target\">Key Risks to the HCG Oncology Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Earnings_Miss_Risk\" title=\"Earnings Miss Risk\">Earnings Miss Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Macro_and_Global_Headwinds\" title=\"Macro and Global Headwinds\">Macro and Global Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Sector-Specific_Risks\" title=\"Sector-Specific Risks\">Sector-Specific Risks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#FII_Outflows\" title=\"FII Outflows\">FII Outflows<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#HCG_Oncology_Financial_Snapshot_FY25_to_FY27\" title=\"HCG Oncology Financial Snapshot FY25 to FY27\">HCG Oncology Financial Snapshot FY25 to FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Technical_Outlook_for_HCG_Oncology_Share_Price\" title=\"Technical Outlook for HCG Oncology Share Price\">Technical Outlook for HCG Oncology Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#What_is_the_HCG_Oncology_share_price_target_for_2026\" title=\"What is the HCG Oncology share price target for 2026?\">What is the HCG Oncology share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Is_HCG_Oncology_a_good_buy_at_Rs_365\" title=\"Is HCG Oncology a good buy at Rs 365?\">Is HCG Oncology a good buy at Rs 365?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#What_is_the_52_week_high_and_low_of_HCG_Oncology\" title=\"What is the 52 week high and low of HCG Oncology?\">What is the 52 week high and low of HCG Oncology?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#What_sector_does_HCG_Oncology_belong_to\" title=\"What sector does HCG Oncology belong to?\">What sector does HCG Oncology belong to?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#What_is_the_bull_case_for_HCG_Oncology_share_price\" title=\"What is the bull case for HCG Oncology share price?\">What is the bull case for HCG Oncology share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#What_are_the_key_risks_to_the_HCG_Oncology_share_price_target\" title=\"What are the key risks to the HCG Oncology share price target?\">What are the key risks to the HCG Oncology share price target?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/hcg-oncology-share-price-target-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"HCG_Oncology_Company_Overview\"><\/span><strong>HCG Oncology Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Tap to Access Best Research on Univest<\/strong><\/a><\/p>\n<p>HCG Oncology (NSE: HCG) is a listed company in India&#8217;s Hospitals sector with a market capitalisation of Rs 3504 crore. At CMP Rs 365 against a 52 week range of Rs 295 to Rs 435, the stock currently offers meaningful upside to the analyst price forecast of Rs 470. For more share price target analysis, visit <a href=\"https:\/\/univest.in\/blogs\"><strong>Univest Blogs<\/strong><\/a>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>HCG<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Hospitals<\/td>\n<\/tr>\n<tr>\n<td>CMP April 2026<\/td>\n<td>Rs 365<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 435<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 295<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 3504 crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>30x<\/td>\n<\/tr>\n<tr>\n<td>12M Analyst Price Forecast<\/td>\n<td>Rs 470<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 564<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 276<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Analysts_Set_the_HCG_Oncology_Share_Price_Target_at_Rs_470_for_2026\"><\/span><strong>Why Analysts Set the HCG Oncology Share Price Target at Rs 470 for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Delivery_and_Revenue_Acceleration\"><\/span><strong>FY27 Earnings Delivery and Revenue Acceleration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>FY27 is the key year where analysts expect HCG Oncology to deliver meaningful PAT growth. This is the primary variable that bridges the gap between the current CMP of Rs 365 and the <strong>HCG Oncology share price target 2026<\/strong> of Rs 470. Analysts project 15 to 20 percent PAT growth in FY27. Track Q4 results live on the <strong>Univest Screener<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_scale-up_from_new_product_launches\"><\/span><strong>Revenue scale-up from new product launches<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue scale-up from new product launches is a key growth driver that analysts highlight in supporting the <strong>HCG Oncology share price target<\/strong> of Rs 470. The Hospitals sector is expanding at 12 to 18 percent annually, and HCG Oncology is well-positioned to capture a rising share. Discover top Hospitals stocks on the <strong>Unives<\/strong><strong>t Scre<\/strong><strong>ener<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margin_expansion_through_operating_leverage\"><\/span><strong>Margin expansion through operating leverage<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Margin expansion through operating leverage provides an additional lever that can help HCG Oncology exceed analyst projections and potentially push the stock toward the bull case target of Rs 564. Compare HCG Oncology with sector peers on the <strong>Univest Screener<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\"><\/span><strong>RBI Rate Cut Cycle and Lower Cost of Capital<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s rate cut cycle that commenced in 2026 reduces HCG Oncology&#8217;s borrowing costs and stimulates end-market demand, supporting the <strong>HCG Oncology share price target 2026<\/strong> of Rs 470.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Union_Budget_2026-27_Policy_Support\"><\/span><strong>Union Budget 2026-27 Policy Support<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Budget 2026-27 capex continuity and PLI scheme extensions create a constructive backdrop for HCG Oncology&#8217;s Hospitals business, directly supporting the <strong>HCG Oncology share price target 2026<\/strong> bull case of Rs 564.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_Base_Case_and_Bear_Case_for_HCG_Oncology_Share_Price_Target\"><\/span><strong>Bull Case, Base Case and Bear Case for HCG Oncology Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target<\/th>\n<th>Key Assumption<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 564<\/td>\n<td>FY27 revenue growth exceeds 25 percent, margin expansion of 200 bps, sector re-rating<\/td>\n<\/tr>\n<tr>\n<td>Base Case Forecast<\/td>\n<td>Rs 470<\/td>\n<td>FY27 revenue growth of 15 to 18 percent, stable margins, current P\/E sustained<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 276<\/td>\n<td>Revenue growth disappoints below 10 percent, margin pressure, valuation de-rating<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For live tracking of HCG Oncology analyst price targets and ratings, use the <strong>Univest Screener<\/strong>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_HCG_Oncology_Share_Price_Target\"><\/span><strong>Key Risks to the HCG Oncology Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Miss_Risk\"><\/span><strong>Earnings Miss Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>If HCG Oncology reports quarterly earnings below expectations, the <strong>HCG Oncology share price target<\/strong> will likely face downward revision. Watch Q4 FY26 results closely on <strong>Univest Screener<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Macro_and_Global_Headwinds\"><\/span><strong>Macro and Global Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The US 26 percent reciprocal tariff announcement of April 2026 has created global macro uncertainty that adds near-term risk to the <strong>HCG Oncology share price target 2026<\/strong> timeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Sector-Specific_Risks\"><\/span><strong>Sector-Specific Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Regulatory changes, input cost volatility, and competitive intensity in the Hospitals space could pressure margins and delay realisation of the <strong>HCG Oncology share price target<\/strong> of Rs 470.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FII_Outflows\"><\/span><strong>FII Outflows<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Continued FII selling in Indian equities could suppress the valuation multiples needed for HCG Oncology to reach its analyst price forecast of Rs 470 within the 12 month horizon.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"HCG_Oncology_Financial_Snapshot_FY25_to_FY27\"><\/span><strong>HCG Oncology Financial Snapshot FY25 to FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>FY25 Actual<\/th>\n<th>FY26 Estimate<\/th>\n<th>FY27 Estimate<\/th>\n<\/tr>\n<tr>\n<td>Revenue (Rs Cr)<\/td>\n<td>Refer NSE filing<\/td>\n<td>Refer NSE filing<\/td>\n<td>Refer NSE\/BSE filing<\/td>\n<\/tr>\n<tr>\n<td>EBITDA Margin<\/td>\n<td>Refer NSE filing<\/td>\n<td>Refer NSE filing<\/td>\n<td>Expected expansion<\/td>\n<\/tr>\n<tr>\n<td>PAT (Rs Cr)<\/td>\n<td>Refer NSE filing<\/td>\n<td>Refer NSE filing<\/td>\n<td>15 to 20 percent growth<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 3504 crore<\/td>\n<td>Higher at 52W peak<\/td>\n<td>Tracks price movement<\/td>\n<\/tr>\n<tr>\n<td>P\/E Ratio<\/td>\n<td>30x<\/td>\n<td>Current level<\/td>\n<td>Target implies re-rating<\/td>\n<\/tr>\n<tr>\n<td>52 Week High \/ Low<\/td>\n<td colspan=\"3\">Rs 435 \/ Rs 295<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>If you want to track HCG Oncology financial metrics, analyst ratings and peer comparisons in real time, <a href=\"https:\/\/univest.in\/screeners\"><strong>check the Univest Screener for live data<\/strong><\/a>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Outlook_for_HCG_Oncology_Share_Price\"><\/span><strong>Technical Outlook for HCG Oncology Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>HCG Oncology is trading at Rs 365, currently attempting to build a base above its 52 week low of Rs 295. The stock needs to reclaim its 200 day moving average to confirm a meaningful recovery trend. The <strong>HCG Oncology share price target<\/strong> of Rs 470 set by analysts assumes fundamental delivery over the next 12 months rather than near-term price action. Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track HCG Oncology live price and set alerts.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>HCG Oncology share price target 2026<\/strong> of Rs 470 reflects analyst conviction on FY27 earnings delivery, structural sector tailwinds, and the favourable domestic macro environment. The bull case of Rs 564 is achievable if the company executes above expectations. Investors should monitor quarterly earnings, FII ownership trends and management commentary closely. For real-time tracking and research, use the <strong>Univest Screener<\/strong>.<\/p>\n<p><em>This article is for informational and educational purposes only and is not investment advice. Univest is SEBI registered (INH000013776). Please consult a SEBI registered financial advisor before making any investment decision.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_HCG_Oncology_share_price_target_for_2026\"><\/span><strong>What is the HCG Oncology share price target for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>HCG Oncology share price target<\/strong> for 2026 is Rs 470 as per the analyst price forecast, implying 29 percent upside from the current price of Rs 365. The bull case target is Rs 564 and the bear case is Rs 276.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_HCG_Oncology_a_good_buy_at_Rs_365\"><\/span><strong>Is HCG Oncology a good buy at Rs 365?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 365, HCG Oncology trades at a trailing P\/E of 30x and offers potential upside to the analyst price forecast of Rs 470. Whether it is a good buy depends on your investment horizon and risk appetite. Always consult a SEBI registered financial advisor.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52_week_high_and_low_of_HCG_Oncology\"><\/span><strong>What is the 52 week high and low of HCG Oncology?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 52 week high of HCG Oncology is Rs 435 and the 52 week low is Rs 295. The current CMP of Rs 365 positions the stock at a meaningful discount to its peak, which is factored into the analyst <strong>HCG Oncology share price target 2026<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_sector_does_HCG_Oncology_belong_to\"><\/span><strong>What sector does HCG Oncology belong to?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>HCG Oncology belongs to India&#8217;s Hospitals sector and trades on NSE with the ticker HCG. Track the entire Hospitals sector on the <strong>Univest Screener<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_bull_case_for_HCG_Oncology_share_price\"><\/span><strong>What is the bull case for HCG Oncology share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case for HCG Oncology share price is Rs 564, which assumes revenue growth exceeding 25 percent in FY27, margin expansion of 200 basis points, and a positive re-rating of the Hospitals sector. This scenario requires strong execution and supportive macro conditions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_HCG_Oncology_share_price_target\"><\/span><strong>What are the key risks to the HCG Oncology share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key risks include earnings miss in upcoming quarters, continued FII selling, regulatory headwinds in the Hospitals sector, raw material cost volatility, and global macro uncertainty driven by the US tariff environment. These risks could push the stock toward the bear case of Rs 276.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-nuvoco-share-price-falling-key-reasons-2026\">Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-capacite-share-price-falling-key-reasons-2026\">Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-psp-projects-share-price-falling-key-reasons-2026\">Why Is PSP Projects Share Price Falling Key Reasons 2026<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>HCG Oncology share price target 2026 is Rs 470. Analyst forecast, bull case Rs 564, bear case Rs 276. Growth catalysts, risks and full analysis. April 2026.<\/p>\n","protected":false},"author":26,"featured_media":84066,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-82950","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1778240597:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["84"],"rank_math_focus_keyword":["HCG Oncology Share Price Target"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["HCG Oncology Share Price Target 2026 Forecast"],"rank_math_description":["HCG Oncology share price target 2026 is Rs 470. Analyst forecast, bull case Rs 564, bear case Rs 276. Growth catalysts, risks and full analysis. April 2026."],"_wp_old_date":["2026-05-07"],"_thumbnail_id":["84066"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["10760"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/08171142\/HCG-Oncology-Share-Price-Target-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/82950","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=82950"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/82950\/revisions"}],"predecessor-version":[{"id":84067,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/82950\/revisions\/84067"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/84066"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=82950"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=82950"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=82950"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}